Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm
Interim guidance - 7 May 2021, updated 15 March 2022
15 March 2022
| COVID-19: Vaccines
Overview
These WHO interim recommendations for use of the COVID-19 vaccine BIBP produced by Sinopharm were
developed on the basis of advice issued by the Strategic Advisory Group
of Experts on Immunization (SAGE) and the evidence summary included in
the background document and annexes referenced below.
This document has been updated: version 15 March 2022.
For translations of this document in other languages, click here.
Related links:
- Annexes to the interim recommendations for use of the inactivated COVID-19 vaccine BIBP
- Background document on the COVID-19 vaccine BIBP
Archived versions:
- Interim recommendations for use of the inactivated COVID-19 vaccine BIBP (Sinopharm). Version 7 May 2021
- Interim recommendations for use of the inactivated COVID-19 vaccine BIBP (Sinopharm). Version 28 October 2021
WHO Team
Immunization, Vaccines and Biologicals (IVB),
WHO Headquarters (HQ)
Editors
World Health Organization
Reference numbers
WHO Reference Number: WHO/2019-nCoV/vaccines/SAGE_recommendation/BIBP/2021.1
Copyright
